For the Department of Agriculture of the United States of America: and Certification:

/s/ Richard E. Rominger
January 30, 1996
Washington, D.C.

For the Food and Drug Administration of the United States of America:

/s/ Mary Pendergast
January 30, 1996
Washington, D.C.

For the State Committee for Sanitary and Epidemiological Surveillance of the Russian Federation:

/s/ G. G. Onitshenko
January 30, 1996
Washington, D.C.

For the Committee of the Russian Federation on Standardization, Metrology, and Certification:

/s/ S. Bezverkhi
March 29, 1996
Moscow, Russian Federation

[FR Doc. 96–14387Filed 6–06–96; 8:45 am]
BILLING CODE 4160–01–F

National Institutes of Health

Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial; Proposed Collection; Comment Request;

SUMMARY: In compliance with the requirement of Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995, for opportunity for public comment on proposed data collection projects, the National Cancer Institute (NCI), the National Institutes of Health (NIH) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.

PROPOSED COLLECTION: *Title:* Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. *Type of Information Collection Request:* EXTENSION, OMB control number 0925–0407, expiration date September 30, 1996. *Need and Use of Information Collection:* This trial is designed to determine if screening for prostate, lung, colorectal and ovarian cancer can reduce mortality from these cancers which currently cause an estimated 251,000 deaths annually in the U.S. The design is a two-armed randomized trial of men and women aged 55 to 74 at entry. The anticipated total sample size, after four and one half years of recruitment, is projected to be 148,000. The primary endpoint of the trial is cancer-specific mortality for each of the four cancer sites (prostate, lung, colorectal, and ovary). In addition, cancer incidence, stage shift, and case survival are to be monitored to help understand and explain results. Biologic prognostic characteristics of the cancers will be measured and correlated with mortality to determine the mortality predictive value of these intermediate endpoints. Basic demographic data, risk factor data for the four cancer sites and screening history data, as collected from all subjects at baseline, will be used to assure comparability between the screening and control groups and make appropriate adjustments in analysis. Further, demographic and risk factor information will be used to analyze the differential effectiveness of screening in high versus low risk individuals. *Frequency of Response:* On occasion. *Affected Public:* Individuals or households. *Type of Respondents:* Adult men and women. The annual reporting burden is as follows: *Estimated Number of Respondents:* 75,333; *Estimated Number of Responses per Respondent:* 1.7; *Average Burden Hours Per Response:* .573; and *Estimated Total Annual Burden Hours Requested:* 73,400. *The annualized cost to respondents is estimated at:* $734,290. There are no Capital Costs to report. There are no Operating or Maintenance Costs to report.

REQUEST FOR COMMENTS: Written comments and/or suggestions from the public and affected agencies should address one or more of the following points: (1) Evaluate whether the proposed collection of information is necessary for the proper performance of the function of the agency, including whether the information will have practical utility; (2) Evaluate the accuracy of the agency's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) Enhance the quality, utility, and clarity of the information to be collected; and (4) Minimize the burden of the collection of information on those who are to respond, including the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology.

FOR FURTHER INFORMATION CONTACT: To request more information on the proposed project or to obtain a copy of the data collection plans and instruments, contact Dr. John Gohagan, Chief, Early Detection Branch, EDCOP, National Cancer Institute, NIH, EPN Building, Room 330, 6130 Executive Boulevard, Bethesda, MD 20892–7346, or call non-toll-free number (301) 496–3982 or E-mail your request, including your address to:
gohaganj@dcpcepn.nci.nih.gov

COMMENTS DUE DATE: Comments regarding this information collection are best assured of having their full effect if received within 60-days of the date of this publication.

Dated: May 30, 1996.
Philip D. Amoruso,
Executive Officer, NCI.

[FR Doc. 96–14431 Filed 6–6–96; 8:45 am]
BILLING CODE 4140–01–M

National Center for Human Genome Research; Notice of Closed Meetings

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix), notice is hereby given of the following meetings of the National Center for Human Genome Research Special Emphasis Panel:

Agenda/Purpose: To review and evaluate grant applications and/or contract proposals.
Name of Committee: National Center for Human Genome Research Special Emphasis Panel 01.
Date: June 24, 1996.
Time: 7:00 p.m.
Place: NIH, Natcher (Building 45), Rooms G1/G2, 9000 Rockville Pike, Bethesda, Maryland
Contact Person: Ms. Linda Engel, Chief, Office of Scientific Review, National Center for Human Genome Research, National Institutes of Health, Building 38A, Room 604, Bethesda, Maryland 20892, (301) 402–0838.

Name of Committee: National Center for Human Genome Research Special Emphasis Panel 02.
Date: June 25, 1996.
Time: 9:00 a.m.
Place: NIH, Natcher (Building 45), Rooms G1/G2, 9000 Rockville Pike, Bethesda, Maryland.
Contact Person: Ms. Linda Engel, Chief, Office of Scientific Review, National Center for Human Genome Research, National Institutes of Health, Building 38A, Room 604, Bethesda, Maryland 20892, (301) 402–0838.

Name of Committee: National Center for Human Genome Research Special Emphasis Panel 03.
Date: June 25, 1996.
Time: 9:00 a.m.
Place: NIH, Natcher (Building 45), Rooms F1/F2, 9000 Rockville Pike, Bethesda, Maryland.
Contact Person: Ms. Linda Engel, Chief, Office of Scientific Review, National Center for Human Genome Research, National Institutes of Health, Building 38A, Room 604, Bethesda, Maryland 20892, (301) 402–0838.

The meetings will be closed in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. The applications and/or contract proposals, and the discussions could reveal confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.